drug development
| 4 min read
Biopharma’s recovery is real, but the data show a sector that now rewards validated biology, late-stage execution, and commercial relevance.
Join this two-day event to learn where drug development is headed and what it means for researchers today.
| 3 min read
AI is reshaping early drug discovery, but persistent translational gaps, biological complexity, and validation challenges limit how far machine learning alone can predict human outcomes.
| 4 min read
Integrating patient-derived xenografts and organoids can help researchers identify responsive tumor subsets, anticipate resistance, and strengthen translational confidence before clinical testing.
| 4 min read
Cancer diagnostic technologies, advances on brain map models, pharmaceutical deals, and more led the news this week.
| 4 min read
As the FDA shifts toward nonclinical methods, scientists weigh whether alternative technologies can match the predictive power of animal studies.
| 9 min read
Industry leaders predict this year will be shaped by AI-driven discovery, human-relevant safety testing, and tighter capital discipline.
| 4 min read
The FDA’s National Priority Voucher program aims to cut standard review times from potentially years to months, raising questions about safety, access, and public health impact.
| 4 min read
Preclinical systems such as patient-derived xenografts are providing unprecedented insight into tumor biology and helping bridge the gap between discovery and clinical translation.
| 2 min read
New study uses simulations and machine learning to identify a single, high-impact interaction within a viral fusion protein, highlighting a potential new target for antiviral drug development.
